Who Supplies Celecoxib to India from CHINA

Importing finished pharmaceutical formulations containing Celecoxib into India requires compliance with the Drugs and Cosmetics Act, 1940, and associated rules. The Central Drugs Standard Control Organization (CDSCO) mandates that all imported drugs be registered and approved before distribution. The registration process involves obtaining a Registration Certificate (Form 41) from CDSCO, which certifies the drug's safety, efficacy, and quality. An Import License from the Directorate General of Foreign Trade (DGFT) is also necessary, allowing the importer to bring the drug into India. The application for registration must include detailed product information, manufacturing details, and evidence of compliance with Good Manufacturing Practices (GMP). The timeline for obtaining these approvals can vary but typically ranges from several months to over a year, depending on the complexity of the product and the completeness of the application. For formulations under HS Code 30049069, specific requirements include providing a Certificate of Pharmaceutical Product (CoPP), stability data (preferably ICH Zone IV), and a No Objection Certificate (NOC) from the manufacturer. It's crucial to ensure that all documentation is accurate and complete to avoid delays in the approval process.

Upon arrival in India, imported pharmaceutical formulations containing Celecoxib are subject to quality testing by CDSCO-approved laboratories. Each batch must undergo testing to confirm compliance with the Indian Pharmacopoeia standards. The Certificate of Analysis (CoA) from the manufacturer should accompany each shipment, detailing the product's composition, manufacturing process, and quality control measures. Stability data, particularly for ICH Zone IV conditions, is essential to demonstrate the product's shelf-life and storage requirements. Port inspection by customs drug inspectors is mandatory to verify the authenticity of the product and ensure it meets all regulatory standards. If a batch fails to meet the required standards, it may be rejected, leading to potential delays, re-exportation, or destruction of the product. Importers should maintain strict quality assurance protocols and ensure that all documentation is readily available to facilitate smooth customs clearance.

Between 2024 and 2026, the Indian government has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. Notably, on April 8, 2025, the CDSCO introduced mandatory import registration and licensing requirements for all imported medicines, including those manufactured in Special Economic Zones (SEZs) intended for domestic sale. This policy aims to prevent the sale of unapproved or illegal medicines in the Indian market. The new regulations stipulate that drugs manufactured in SEZs for export purposes are not permitted for transfer to the Domestic Tariff Area (DTA) for sale and distribution. Additionally, the Production Linked Incentive (PLI) scheme, introduced to boost domestic manufacturing, may impact the import of finished formulations by encouraging local production. Importers should stay informed about these policy changes to ensure compliance and adjust their sourcing strategies accordingly.

India imports finished Celecoxib formulations primarily due to the demand for branded or patented products not manufactured domestically. Specific dosage forms, such as certain capsule strengths or combination therapies, may not be produced locally, necessitating imports. While India has a robust pharmaceutical manufacturing sector, the import of finished formulations allows for a diverse product range and meets unmet medical needs. The market size for Celecoxib formulations in India is substantial, with imports contributing to a significant portion of the total market value. This import dependency underscores the importance of international trade in fulfilling domestic pharmaceutical requirements.

The import of finished pharmaceutical formulations containing Celecoxib (HS Code 30049069) into India is subject to a Basic Customs Duty (BCD) of 10%. Additionally, a Social Welfare Surcharge (SWS) of 10% on the BCD is applicable. The Integrated Goods and Services Tax (IGST) is levied at 12% on the total value, including the BCD and SWS. This results in a total landed duty of approximately 23.536% of the Cost, Insurance, and Freight (CIF) value. Importers should account for these duties when calculating the total cost of imported formulations. It's important to note that duty rates are subject to change; therefore, importers should consult the latest customs notifications and consider any applicable exemptions or preferential rates.

India sources finished Celecoxib formulations from China due to several competitive advantages. Chinese manufacturers often offer cost-effective pricing, which is attractive for price-sensitive markets. Additionally, China has the capability to produce specialized dosage forms and formulations that may not be readily available from other suppliers. While other countries, such as Germany and the United States, also supply Celecoxib formulations, China's competitive pricing and manufacturing capabilities make it a preferred source for Indian importers. China's share in the Indian market for Celecoxib formulations is significant, reflecting its strong position as a supplier.

India imports finished Celecoxib formulations from China due to strategic reasons, including the availability of patented formulations and specialized dosage forms not produced domestically. China's manufacturing capabilities allow for the production of specific formulations that meet the therapeutic needs of the Indian market. Additionally, technology-licensed products from China offer advanced formulations that may not be available from other sources.

When comparing China to other origins such as the European Union and the United States, China offers competitive pricing and a diverse range of formulations. While the EU and the US may provide higher-quality products, they often come at a premium price. China's unique advantage lies in its ability to offer cost-effective solutions without compromising on quality, making it an attractive source for Indian importers.